Federal contractor · DURHAM, NC

EYDIS BIO, INC.

No contract obligations recorded for EYDIS BIO, INC. in FY2026. Since FY2025: $499.8K. Its largest customer was National Institutes of Health ($0). It also received $406.5K in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
1
Sole-source
—
Single offer
—
UEI
MWWCM7JMBCF1
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 499.8KFY2025
  2. 0FY2026

Top buying agencies

Obligations in FY2026.

  1. National Institutes of Health$00.0%
    1 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

  1. PERFORM A STRUCTURE ACTIVITY RELATIONSHIP (SAR), MOLECULAR BINDING AND METABOLISM OF THE LEAD SCAFFOLD (HS-176) TO GUIDE THE DEVELOPMENT OF MORE POTENT AND DRUG LIKE ANALOGS, AND PRIORITIZATION OF LEAD ANALOGS THROUGH IN VITRO EFFICACY SCREENING AND$499.8K
    National Institutes of Health· Durham County, NC· Research & development· Sep 29, 2025 – Sep 2, 2026· 75N93025C00040

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

EYDIS BIO, INC. received $406.5K in federal assistance in FY2026, on 3 actions (1 new awards), −71% vs FY2025. Its largest program was 93.395 · Cancer Treatment Research ($406.5K).

Assistance · FY2026
$406.5K
New awards
1
Actions
3
Since FY2021
$6.3M

Assistance by fiscal year

  1. 1.6MFY2021
  2. 1.2MFY2022
  3. 1.7MFY2024
  4. 1.4MFY2025
  5. 406.5KFY2026

By type

  1. Grants$406.5K100%

Top programs

  1. 93.395 · Cancer Treatment Research$406.5K100%

Awarding agencies

  1. National Institutes of Health$406.5K100%
    Department of Health and Human Services

Largest awards

  1. NOVEL COMPOUNDS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE - PROJECT SUMMARY / ABSTRACT SYSTEMIC…$2.6M
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Jul 10, 2024 – Apr 1, 2026· R44HL170834
  2. DEVELOPMENT OF ORALLY BIOAVAILABLE AND BLOOD-BRAIN BARRIER PENETRANT, SMALL MOLECULE TAK1 INHIBITORS AS A NOVEL TREATMENT FOR ALZHEIMER'S…$506.3K
    93.866 · Aging Research· National Institutes of Health· Project grant· Sep 12, 2024 – Jul 13, 2026· R41AG090212
  3. DEVELOPMENT OF A NOVEL, ORALLY BIOAVAILABLE, TAK1 INHIBITOR FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - PROJECT…$406.5K
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Sep 16, 2026 – Sep 16, 2026· R43CA310084

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. GENCYTE THERAPEUTICS INC$500K−100% in FY2026
    SAN CARLOS, CA · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. NOMOCAN PHARMACEUTICALS LLC$499.2K−100% in FY2026
    NEW YORK, NY · 99.9% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. COCRYSTAL PHARMA, INC.$498.2K−100% in FY2026
    BOTHELL, WA · 99.7% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.